These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1699316)

  • 21. G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
    Oeckl P; Hengerer B; Ferger B
    Exp Neurol; 2014 Jul; 257():1-9. PubMed ID: 24747358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation by the neuropeptide cholecystokinin (CCK-8S) of protein phosphorylation in the neostriatum.
    Snyder GL; Fisone G; Morino P; Gundersen V; Ottersen OP; Hökfelt T; Greengard P
    Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11277-81. PubMed ID: 8248241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DARPP-32, a dopamine-regulated phosphoprotein.
    Hemmings HC; Greengard P
    Prog Brain Res; 1986; 69():149-59. PubMed ID: 3328873
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibitors of protein phosphatase-1. Inhibitor-1 of bovine adipose tissue and a dopamine- and cAMP-regulated phosphoprotein of bovine brain are identical.
    Strålfors P; Hemmings HC; Greengard P
    Eur J Biochem; 1989 Mar; 180(1):143-8. PubMed ID: 2540000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions.
    Grebb JA; Girault JA; Ehrlich M; Greengard P
    J Neurochem; 1990 Jul; 55(1):204-7. PubMed ID: 2192014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia.
    Håkansson K; Lindskog M; Pozzi L; Usiello A; Fisone G
    Parkinsonism Relat Disord; 2004 Jul; 10(5):281-6. PubMed ID: 15196506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical evidence for the existence of a dopamine- and cyclic AMP-regulated phosphoprotein (DARPP-32) in brown adipose tissue of pigs.
    Meister B; Fried G; Hökfelt T; Hemmings HC; Greengard P
    Proc Natl Acad Sci U S A; 1988 Nov; 85(22):8713-6. PubMed ID: 2847173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
    Coccurello R; Breysse N; Amalric M
    Neuropsychopharmacology; 2004 Aug; 29(8):1451-61. PubMed ID: 15039773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons.
    Hamada M; Higashi H; Nairn AC; Greengard P; Nishi A
    J Neurochem; 2004 Sep; 90(5):1094-103. PubMed ID: 15312165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenosine 3',5'-cyclic monophosphate/vanadate-sensitive phosphorylation of DARPP-32- and inhibitor-1-immunoreactive proteins.
    Edgar MA; Dokas LA
    Recept Signal Transduct; 1997; 7(1):13-28. PubMed ID: 9285528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonistic effects of dopaminergic signaling and ethanol on protein kinase A-mediated phosphorylation of DARPP-32 and the NR1 subunit of the NMDA receptor.
    Edwards S; Simmons DL; Galindo DG; Doherty JM; Scott AM; Hughes PD; Wilcox RE
    Alcohol Clin Exp Res; 2002 Feb; 26(2):173-80. PubMed ID: 11964556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man.
    Raisman-Vozari R; Girault JA; Moussaoui S; Feuerstein C; Jenner P; Marsden CD; Agid Y
    Brain Res; 1990 Jan; 507(1):45-50. PubMed ID: 2105823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine and cyclic AMP-regulated phosphoprotein-32 phosphorylation pattern in cocaine and morphine-sensitized rats.
    Scheggi S; Rauggi R; Gambarana C; Tagliamonte A; De Montis MG
    J Neurochem; 2004 Aug; 90(4):792-9. PubMed ID: 15287884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excitatory amino acids and Parkinson's disease.
    Schmidt WJ; Bubser M; Hauber W
    Trends Neurosci; 1990 Feb; 13(2):46-7. PubMed ID: 1690929
    [No Abstract]   [Full Text] [Related]  

  • 35. Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling.
    Matsuyama S; Fukui R; Higashi H; Nishi A
    Eur J Neurosci; 2003 Sep; 18(5):1247-53. PubMed ID: 12956723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission.
    Fienberg AA; Hiroi N; Mermelstein PG; Song W; Snyder GL; Nishi A; Cheramy A; O'Callaghan JP; Miller DB; Cole DG; Corbett R; Haile CN; Cooper DC; Onn SP; Grace AA; Ouimet CC; White FJ; Hyman SE; Surmeier DJ; Girault J; Nestler EJ; Greengard P
    Science; 1998 Aug; 281(5378):838-42. PubMed ID: 9694658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mesolimbic dopaminergic response to novel palatable food consumption increases dopamine-D1 receptor-mediated signalling with complex modifications of the DARPP-32 phosphorylation pattern.
    Rauggi R; Scheggi S; Cassanelli A; De Montis MG; Tagliamonte A; Gambarana C
    J Neurochem; 2005 Feb; 92(4):867-77. PubMed ID: 15686489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites.
    Lindgren N; Usiello A; Goiny M; Haycock J; Erbs E; Greengard P; Hokfelt T; Borrelli E; Fisone G
    Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4305-9. PubMed ID: 12651945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DARPP-32: an integrator of neurotransmission.
    Svenningsson P; Nishi A; Fisone G; Girault JA; Nairn AC; Greengard P
    Annu Rev Pharmacol Toxicol; 2004; 44():269-96. PubMed ID: 14744247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A.
    Nishi A; Bibb JA; Matsuyama S; Hamada M; Higashi H; Nairn AC; Greengard P
    J Neurochem; 2002 May; 81(4):832-41. PubMed ID: 12065642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.